Developer docs
API playgroundTry for free, no card

Search company profiles

Limbix

Full company profile

uuid000253g

Namestring
Limbix
Legal namestring
Limbix Health Inc.
Websiteurl
limbix.com
Company typeenum
Private
Founded yearint
2016
Descriptiontext

Limbix was a San Francisco-based digital therapeutics company founded in 2016 that developed prescription software for adolescent mental health. The company's core product was SparkRx, a digital therapeutic application designed to treat depression in adolescents, which the company reported had shown positive clinical results. The platform was positioned as a frontline digital treatment option for teenage depression, targeting a narrow, underserved population with limited digital therapeutic alternatives.

Limbix operated with a lean 11-50 employee organization and concentrated its development effort on a single primary product in the adolescent mental health vertical. Its technology stack centered on mobile-delivered therapeutic content and protocols validated through clinical study, rather than on AI-driven personalization or data analytics layers. The company carried out no publicly disclosed integration, API, or SDK offerings, suggesting a direct-to-patient or provider-prescribed distribution model rather than a platform play.

Commercially, Limbix generated revenue through digital therapeutic product sales, structured as a recurring subscription model, from the commercialization of SparkRx and planned pediatric mental health offerings. The company raised approximately $31 million across six funding events between 2016 and 2021, culminating in a $15 million Series A2 led by GSR Ventures in December 2021 earmarked for commercialization and staffing. In July 2023, Limbix was acquired by Big Health Inc., a digital therapeutics provider focused on non-drug therapies, integrating SparkRx and planned teen anxiety products into Big Health's broader portfolio.

Short descriptiontext

Limbix is a digital therapeutics company that developed SparkRx, a prescription mobile application for treating depression in adolescents. Founded in 2016 and based in San Francisco, it was acquired by Big Health in July 2023.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersPalo Alto, United States
HQ citystring
Palo Alto
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
digital therapeutics, pediatric mental health, adolescent depression treatment, prescription digital therapeutics, behavioral health software
Industry4 codes
PRIMARYHLACANAA
Condition-specific Digital Therapeutics (DTx)
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHLACANAL
Pediatrics & Adolescent Therapeutics (Digital)
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHLAEAHAJ
Behavioral Health Digital Therapeutics (DTx) & Virtual Care Partner Management
SECONDARYHLACANAO
DTx/SaMD Deployment, Integration & Reimbursement Enablement
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
NAICS code1 code
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
SIC code2 codes
  • Surgical & Medical Instruments & Apparatus3841
  • Electromedical & Electrotherapeutic Apparatus3845
Product category
Digital Therapeutics
Social media profiles1 record
Revenue model1 record
1Digital Therapeutic Product Revenue
TypeSubscription Recurring
Description

Revenue generated from commercialization of digital therapeutic products such as SparkRx for adolescent depression and potential future pediatric mental health digital therapeutics.

biospace.com
Cost components4 values
Personnel, Technology or R&D, Marketing or Sales, Operations
GTM typeB2C
B2C
Offering typeSoftware
Software
Core offering1 text field

Limbix developed and commercialized SparkRx, a prescription digital therapeutic mobile application designed to treat depression in adolescents. The product was positioned as a frontline digital treatment option for teenage depression, supported by positive clinical results, and represented the company's primary offering within a focused adolescent mental health portfolio.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • SparkRx showed positive clinical results in treating adolescent depression.
Product overview1 text field

Limbix is a digital therapeutic company that developed mental health treatments for adolescents. The company offers a single primary product, SparkRx, which is a digital therapeutic app designed to treat depression in teenagers. SparkRx represents the core offering within Limbix's adolescent mental health portfolio. In July 2023, Limbix was acquired by Big Health Inc., expanding Big Health's portfolio to include SparkRx for teenage depression and teen anxiety products.

Product and service1 record
1SparkRx
CategoryDigital Therapeutics
Description

SparkRx is a prescription digital therapeutic mobile application designed to treat depression in adolescents. It serves as a frontline digital treatment option for teenage depression, with positive clinical results supporting its efficacy. The product is intended for adolescents experiencing depression and related mental health conditions, and was integrated into Big Health's portfolio following the July 2023 acquisition.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
1Pear Therapeutics
TypeDirect peer
Description

Pear Therapeutics was a leading prescription digital therapeutics company developing FDA-authorized software-based treatments across multiple indications including mental health. Closely comparable to Limbix in prescription DTx commercialization model and clinical-evidence-driven approach.

2Better Therapeutics
TypeDirect peer
Description

Better Therapeutics is a prescription digital therapeutics company developing software-based treatments for cardiometabolic and related conditions. Comparable to Limbix as a clinical-stage prescription DTx pursuing payer reimbursement for software-delivered therapies.

TypeDirect peer
Description

Mahana Therapeutics is a prescription digital therapeutics company focused on conditions including IBS and mental health. Comparable to Limbix in the prescription DTx category with similar regulatory and reimbursement pathways.

TypeDirect peer
Description

Cognoa develops FDA-authorized digital diagnostics and therapeutics for pediatric developmental conditions such as autism. Highly comparable to Limbix as a pediatric-focused digital health company pursuing FDA-authorized digital products for children and adolescents.

TypeEmerging player
Description

Brightline is a pediatric and adolescent mental health platform combining teletherapy, coaching, and digital tools. Comparable to Limbix in its exclusive focus on pediatric/adolescent mental health, though delivered via services rather than prescription software.

TypeBroad incumbent
Description

Headspace Health (formed via the Ginger-Headspace merger) is a scaled behavioral health platform offering mental health support including therapy and coaching. Overlaps with Limbix's adolescent mental health positioning as a major commercial competitor for patient and payer mindshare.

TypeBroad incumbent
Description

Talkspace is a publicly traded virtual behavioral health platform providing therapy and psychiatry services including for adolescents. Comparable to Limbix as an adolescent-accessible mental health treatment option competing for the same clinician-prescribed treatment pathways.

TypeEmerging player
Description

BehaVR develops virtual reality-based digital therapeutics for mental health conditions including anxiety and depression. Comparable to Limbix as a digital therapeutics peer pursuing FDA-aligned, evidence-based software treatments for mental health indications.

TypeBroad incumbent
Description

Big Health is the digital therapeutics company that acquired Limbix in 2023. It develops prescription digital therapeutics for insomnia (Sleepio) and anxiety (Daylight) — overlapping condition-specific DTx focus and now direct portfolio adjacency to Limbix's adolescent depression asset.

TypeDirect peer
Description

Akili Interactive is an FDA-cleared prescription digital therapeutics company whose lead product (EndeavorRx) targets pediatric ADHD. Comparable to Limbix as a prescription DTx company focused on pediatric/adolescent mental and cognitive health indications.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors22 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Limbix

Digital Therapeuticslimbix.com

Limbix is a digital therapeutics company that developed SparkRx, a prescription mobile application for treating depression in adolescents. Founded in 2016 and based in San Francisco, it was acquired by Big Health in July 2023.

What Limbix does

Limbix was a San Francisco-based digital therapeutics company founded in 2016 that developed prescription software for adolescent mental health. The company's core product was SparkRx, a digital therapeutic application designed to treat depression in adolescents, which the company reported had shown positive clinical results. The platform was positioned as a frontline digital treatment option for teenage depression, targeting a narrow, underserved population with limited digital therapeutic alternatives.

Limbix operated with a lean 11-50 employee organization and concentrated its development effort on a single primary product in the adolescent mental health vertical. Its technology stack centered on mobile-delivered therapeutic content and protocols validated through clinical study, rather than on AI-driven personalization or data analytics layers. The company carried out no publicly disclosed integration, API, or SDK offerings, suggesting a direct-to-patient or provider-prescribed distribution model rather than a platform play.

Commercially, Limbix generated revenue through digital therapeutic product sales, structured as a recurring subscription model, from the commercialization of SparkRx and planned pediatric mental health offerings. The company raised approximately $31 million across six funding events between 2016 and 2021, culminating in a $15 million Series A2 led by GSR Ventures in December 2021 earmarked for commercialization and staffing. In July 2023, Limbix was acquired by Big Health Inc., a digital therapeutics provider focused on non-drug therapies, integrating SparkRx and planned teen anxiety products into Big Health's broader portfolio.

Limbix firmographics

Firmographics
Name
Limbix
Legal name
Limbix Health Inc.
Website
https://limbix.com
Company type
Private
Founded year
2016
Operating status
Acquired
Headcount range
1–10 employees
Short description
Limbix is a digital therapeutics company that developed SparkRx, a prescription mobile application for treating depression in adolescents. Founded in 2016 and based in San Francisco, it was acquired by Big Health in July 2023.
Ownership category
akta.pro rank

Limbix industry classification

Industry
Product category
Digital Therapeutics
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
SIC
Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845)
akta.pro industry
PRIMARYHLACANAA
Condition-specific Digital Therapeutics (DTx)
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHLACANAL
Pediatrics & Adolescent Therapeutics (Digital)
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHLAEAHAJ
Behavioral Health Digital Therapeutics (DTx) & Virtual Care Partner Management
SECONDARYHLACANAO
DTx/SaMD Deployment, Integration & Reimbursement Enablement
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)

Keywords

  • Digital therapeutics
  • Pediatric mental health
  • Adolescent depression treatment
  • Prescription digital therapeutics
  • Behavioral health software

Where Limbix is headquartered

Location

Headquarters

HQ city
Palo Alto
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Limbix business model

Business model
GTM type
B2C
Offering type
Software
Cost components
Personnel, Technology or R&D, Marketing or Sales, Operations

Revenue model

  1. Digital Therapeutic Product Revenue: Revenue generated from commercialization of digital therapeutic products such as SparkRx for adolescent depression and potential future pediatric mental health digital therapeutics.

Limbix product offering

Product offering

Core offering

Limbix developed and commercialized SparkRx, a prescription digital therapeutic mobile application designed to treat depression in adolescents. The product was positioned as a frontline digital treatment option for teenage depression, supported by positive clinical results, and represented the company's primary offering within a focused adolescent mental health portfolio.

Product overview

Limbix is a digital therapeutic company that developed mental health treatments for adolescents. The company offers a single primary product, SparkRx, which is a digital therapeutic app designed to treat depression in teenagers. SparkRx represents the core offering within Limbix's adolescent mental health portfolio. In July 2023, Limbix was acquired by Big Health Inc., expanding Big Health's portfolio to include SparkRx for teenage depression and teen anxiety products.

Differentiator

Problem solved

Functional benefit

Products and services

  • SparkRx SparkRx is a prescription digital therapeutic mobile application designed to treat depression in adolescents. It serves as a frontline digital treatment option for teenage depression, with positive clinical results supporting its efficacy. The product is intended for adolescents experiencing depression and related mental health conditions, and was integrated into Big Health's portfolio following the July 2023 acquisition.

Quantifiable outcome

  • SparkRx showed positive clinical results in treating adolescent depression.

Companies that use Limbix

Customer profile

Segments2 records

Ideal customer profiles2 records

Limbix technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Limbix partnerships and signals

Strategic signal

Scale indicators2 records

Recent moves6 records

Expansion highlights4 records

Limbix competitors and assessment

Company assessment

Direct peers

  • Pear Therapeutics: Pear Therapeutics was a leading prescription digital therapeutics company developing FDA-authorized software-based treatments across multiple indications including mental health. Closely comparable to Limbix in prescription DTx commercialization model and clinical-evidence-driven approach.
  • Better Therapeutics: Better Therapeutics is a prescription digital therapeutics company developing software-based treatments for cardiometabolic and related conditions. Comparable to Limbix as a clinical-stage prescription DTx pursuing payer reimbursement for software-delivered therapies.
  • Mahana Therapeutics: Mahana Therapeutics is a prescription digital therapeutics company focused on conditions including IBS and mental health. Comparable to Limbix in the prescription DTx category with similar regulatory and reimbursement pathways.
  • Cognoa: Cognoa develops FDA-authorized digital diagnostics and therapeutics for pediatric developmental conditions such as autism. Highly comparable to Limbix as a pediatric-focused digital health company pursuing FDA-authorized digital products for children and adolescents.
  • Akili Interactive: Akili Interactive is an FDA-cleared prescription digital therapeutics company whose lead product (EndeavorRx) targets pediatric ADHD. Comparable to Limbix as a prescription DTx company focused on pediatric/adolescent mental and cognitive health indications.

Emerging players

  • Brightline: Brightline is a pediatric and adolescent mental health platform combining teletherapy, coaching, and digital tools. Comparable to Limbix in its exclusive focus on pediatric/adolescent mental health, though delivered via services rather than prescription software.
  • BehaVR: BehaVR develops virtual reality-based digital therapeutics for mental health conditions including anxiety and depression. Comparable to Limbix as a digital therapeutics peer pursuing FDA-aligned, evidence-based software treatments for mental health indications.

Broad incumbents

  • Headspace Health (Ginger): Headspace Health (formed via the Ginger-Headspace merger) is a scaled behavioral health platform offering mental health support including therapy and coaching. Overlaps with Limbix's adolescent mental health positioning as a major commercial competitor for patient and payer mindshare.
  • Talkspace: Talkspace is a publicly traded virtual behavioral health platform providing therapy and psychiatry services including for adolescents. Comparable to Limbix as an adolescent-accessible mental health treatment option competing for the same clinician-prescribed treatment pathways.
  • Big Health: Big Health is the digital therapeutics company that acquired Limbix in 2023. It develops prescription digital therapeutics for insomnia (Sleepio) and anxiety (Daylight) — overlapping condition-specific DTx focus and now direct portfolio adjacency to Limbix's adolescent depression asset.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

Limbix social profiles

Digital presence

Limbix financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Limbix leadership team

Management profile

Number of profiles

Profiles3 records

Limbix funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors22 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Limbix M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Limbix

What does Limbix do?

Limbix developed and commercialized SparkRx, a prescription digital therapeutic mobile application designed to treat depression in adolescents. The product was positioned as a frontline digital treatment option for teenage depression, supported by positive clinical results, and represented the company's primary offering within a focused adolescent mental health portfolio.

Is Limbix a public or private company?

Limbix is a private company. It is classified as corporate owned and is currently acquired.

When was Limbix founded?

Limbix was founded in 2016. It employs 1 to 10 people.

Where is Limbix based?

Limbix is headquartered in Palo Alto, United States, in the North America region.

How does Limbix make money?

One revenue line is on record: digital Therapeutic Product Revenue.

Who are Limbix's main competitors?

Direct peers on record are Pear Therapeutics, Better Therapeutics, Mahana Therapeutics, Cognoa and Akili Interactive. Emerging players are Brightline and BehaVR. Broad incumbents are Headspace Health (Ginger), Talkspace and Big Health.

Does Limbix have an API?

No public API is recorded for Limbix.

What industry is Limbix in?

Limbix's product category is Digital Therapeutics. Its primary akta.pro industry code is HLACANAA, Condition-specific Digital Therapeutics (DTx), with a secondary code of HLACANAL, Pediatrics & Adolescent Therapeutics (Digital). Its NAICS code is 334510 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
openPR.comLeading Companies Fueling Growth and Innovation in the Digital Mental Health MarketThe digital mental health market is projected to reach $58.67 billion by 2030, growing at a compound annual growth rate of 16.3%, driven by AI integration, virtual reality therapy, wearable devices, and expanded hospital adoption. In July 2023, US-based digital health company Big Health acquired Limbix, a US firm specializing in adolescent mental health digital therapeutics, to broaden its portfolio of frontline digital treatment options. Additionally, in August 2023, Aiberry launched an updated AI-powered mental health screening platform tailored for corporate wellness programs, featuring speech and facial expression analysis capabilities.openPR.comKey Factors and Emerging Trends Shaping the Mental Health Market LandscapeThe mental health market is projected to grow from its current size to $512.77 billion by 2030, representing a compound annual growth rate of 3.1%, driven by telehealth adoption, wearable devices, AI diagnostics, and online therapy platforms. In July 2023, US-based Big Health Inc., known for digital non-drug therapies, acquired Limbix Health Inc., a company specializing in adolescent mental health treatment, broadening its portfolio to include SparkRx for teenage depression and expanding into teen anxiety products. The article also details market segments by disorder type, service type, and age group, covering conditions from depression and anxiety to schizophrenia and eating disorders.openPR.comKey Factors and Emerging Trends Shaping the Generalized Anxiety Disorder Market LandscapeThe Business Research Company published a market intelligence report projecting the generalized anxiety disorder market to reach $9.72 billion by 2030, growing at a compound annual growth rate of 4.4%. The report identifies digital therapeutics, telehealth adoption, cognitive behavioral therapy acceptance, and pharmacological treatment expansion as key growth drivers for the sector. A notable industry transaction highlighted is Big Health's acquisition of Limbix Health Inc. in July 2023, aimed at strengthening digital mental health offerings for young people.openPR.comEmerging Sub-Segments Transforming the Dysthymia Market LandscapeThe dysthymia market is expected to reach a valuation of $21.87 billion by 2030, driven by advancements in treatment methods, increased mental health awareness, and digital health innovations. Key players include Pfizer Inc., Johnson & Johnson, and Big Health Inc., which recently acquired Limbix Health Inc. to expand its digital therapeutic offerings. The market is characterized by growing adoption of telepsychiatry, personalized treatments, and digital cognitive therapy tools.openPR.comOverview of the Digital Therapeutics Market: Key Trends, Market Structure, and Top Player AnalysisThe digital therapeutics market is projected to reach $37.82 billion by 2030 with a 28.1% CAGR, driven by technological advancements, AI-powered treatment platforms, and increased adoption of software-driven therapeutic tools in healthcare systems. In July 2023, Big Health, a US-based digital therapeutics provider, acquired Limbix to expand its portfolio with adolescent-focused digital therapies, while Better Therapeutics launched AspyreRx, a prescription digital therapeutic for type 2 diabetes that demonstrated sustained improvements in HbA1c levels and weight reduction.Grand View ResearchDigital Therapeutics Market Size And Share Report, 2030The global digital therapeutics market was valued at USD 6.2 billion in 2023 and is projected to grow at a compound annual growth rate of 27.2% from 2024 to 2030, reaching USD 32.52 billion. Key growth drivers include rising smartphone penetration, increasing demand for patient-centric care, the COVID-19 pandemic's acceleration of digital health adoption, and the growing prevalence of chronic diseases. The market is seeing significant M&A activity, with notable transactions including Akili Interactive Labs being acquired for USD 34 million and BigHealth's acquisition of Limbix Health, while North America led the market with a 40.43% revenue share in 2023.Pharmaceutical TechnologyQ&A: Increasing awareness around digital therapeutics key to realising full potentialAndy Molnar, CEO of the Digital Therapeutics Alliance (DTA), discusses the challenges and future outlook for digital therapeutics (DTx) in an exclusive Q&A, identifying awareness as the industry's primary hurdle, alongside regulatory categorization and reimbursement complexities. The interview highlights Pear Therapeutics' closure as a cautionary example of poor runway management rather than solely a reimbursement failure, while noting recent positive momentum including the Dario Health-Sanofi partnership, MEDRhythm's FDA breakthrough device clearance, and Big Health's acquisition of Limbix. The DTA is actively pursuing education initiatives through PatientPoint in over 20,000 US provider offices and advocates for the Access to Prescription Digital Therapeutics Act of 2023 to enable Medicare coverage, with international progress in Germany, France, the UK, South Korea, and Singapore.CtipmedtechCTIP Announces COVID-19 FlexGrants WinnersThe West Coast Consortium for Technology & Innovation in Pediatrics (CTIP) announced four winners of its COVID-19 FlexGrants, providing up to $15,000 each to pediatric medical device innovators. The selected companies—Aidar Health, Limbix, Melio, and X-Biomedical—received funding to develop or adapt technologies addressing pediatric needs during the pandemic, including diagnostics, mental health support, pathogen testing, and ventilator modifications.